Despite Wednesday's mostly positive reaction across assets, some market participants were contemplating scenarios in which the economy could still slow to a crawl or the dollar can continue on a ...

Canadian politicians are promising to build millions of homes—an unrealistic plan not grounded in reality. The good news is ...

Analysts at BMO Capital Markets expect Summit and Akeso’s HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

BMO Capital analyst Jeffrey Silber lowered the firm’s price target on Moody’s (MCO) to $456 from $481 and keeps a Market Perform rating on the ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Despite his criticisms, Trump ultimately opted against removing Powell and thus avoided any legal fights that could ensue.

Fintel reports that on April 17, 2025, BMO Capital upgraded their outlook for Trex (NYSE:TREX) from Market Perform to ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Google illegally acted to preserve “monopoly power” in the ad-tech business, a federal judge ruled Thursday. It’s the second ...

Fintel reports that on April 17, 2025, BMO Capital downgraded their outlook for Novo Nordisk A (NYSE:NVO) from Outperform to ...

Tariff-driven volatility has redefined what's considered a "normal" day of bond-market trading, with traders contemplating "a wider scope of conceivable outcomes" as the global trade war unfolds, said ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...